Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline

Brelovitug is an investigational IgG1 monoclonal antibody targeting HBsAg on HBV and HDV, showing potent pan-genotypic activity. Credit: Jo Panuwat D / Shutterstock.com.